PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
Sickle Cell Disease
About this trial
This is an interventional treatment trial for Sickle Cell Disease focused on measuring sickle cell disease
Eligibility Criteria
Inclusion Criteria: Male or female, 10 years of age or older on the day of dosing, and generally healthy as determined by medical history, physical examination, and laboratory test values Diagnosis of sickle cell anemia (Hb SS) For female of child-bearing potential, a negative serum pregnancy test and using an adequate method of contraception Has signed and received a copy of the written informed consent form approved by the investigator's Institutional Review Board (IRB), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by this protocol Exclusion Criteria: History of sickle-cell-related pain crisis within two weeks of study Pregnant or breast feeding Transfusion within last 90 days Creatinine >1.5 X upper limit of normal SGPT > 2 X upper limit of normal History of allergic reaction to arginine or citrulline product Requires chronic medication other than study drug that cannot be discontinued during the study period Unable to take or tolerate oral medications Unreliable venous access Noncompliant with regular care Participation in an investigational drug or medical device study within previous 30 days In the opinion of the investigator is not a good candidate for participation in the study
Sites / Locations
- Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Health System